Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN008 vs Xolair in chronic spontaneous urticaria
CTR20210213Phase 3Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by CSPC Baike Biopharmaceutical. Started Mar 2021; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20210213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210213.